Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Bělohlávek… - Circulation, 2020 - Am Heart Assoc
Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
AM Jackson, P Dewan, IS Anand, J Belohlavek… - Circulation, 2020 - diva-portal.org
BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
[HTML][HTML] Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Bělohlávek… - Circulation, 2020 - ncbi.nlm.nih.gov
BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
[PDF][PDF] Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
AM Jackson, JJV McMurray - Circulation, 2020 - dapatrial.org
BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Bělohlávek… - …, 2020 - ingentaconnect.com
Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
AM Jackson, JJV McMurray - Circulation, 2020 - Am Heart Assoc
BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Belohlavek… - Circulation, 2020 - research.rug.nl
Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Bělohlávek… - Circulation, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> In the DAPA-HF trial
(Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), the sodium-glucose …
(Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), the sodium-glucose …
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
AM Jackson, P Dewan, IS Anand, J Bělohlávek… - Circulation, 2020 - europepmc.org
Background In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Bělohlávek… - …, 2020 - research.regionh.dk
BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …